Stimulated by the news of the upcoming listing of Huada Gene, the concept of gene sequencing has been active recently. On the 27th, Daan's genes rose, and Dean Diagnostics, Hokuriku Pharmaceutical, Zhongyuan Concord, Qianshan Pharmaceutical, Anke Bio, and Wuyuan Medicine all strengthened. On June 27, Huada Gene released an initial public offering of a share and a letter of intent for listing on the GEM. It plans to publicly issue no more than 40.1 million shares and raise funds of 484 million yuan. It is reported that the company's business mainly focuses on the provision of genomics diagnosis and research services for medical institutions, scientific research institutions, enterprises and institutions through genetic testing and other means, of which reproductive health services account for more than 50%. Gene sequencing is a novel gene detection technology that analyzes the entire sequence of genes from blood or saliva to predict the likelihood of multiple diseases. At present, the gene sequencing industry chain is mainly composed of upstream sequencing equipment, reagent consumable suppliers, midstream sequencing services, analysis software suppliers, and downstream end users. Among them, the mid-stream sequencing service providers have a dominant position in the industry chain with their unique technologies. Currently, companies engaged in gene sequencing services mainly include illumina, roche, pacific, lifetech, huada gene, daan gene and shellfish. Rui and Kang and so on. According to the agency, gene sequencing has become one of the emerging areas of rapid development in China. Since the country put forward " precise medical care " in 2015, the strategic position of the gene sequencing industry has become prominent, and it has been sought after by many experts and investors in the industry. The listing of Huada Gene will greatly enhance the awareness and confidence of the whole society in the sequencing industry, and continue to be optimistic that the gene sequencing industry will grow rapidly under the leadership of leading enterprises. Related concept stocks: Daan Gene: The overall performance of the company is growing steadily, and the structural changes in the business are the indicators of changes in the industry. In 2016, the company achieved operating income of 1.613 billion yuan, a year-on-year increase of 9.38%; total profit of 152 million yuan, an increase of 11.26%; net profit attributable to the parent company of 107 million yuan, an increase of 5. 38%. Earnings per share was 0.15 yuan. The overall performance has grown steadily, and the structural changes in the sub-business are worthy of attention: the 2016 annual report shows that the company's service business is 620 million yuan, up 27.7% year-on-year; the reagent business income is 730 million yuan, up 36.5 year-on-year. %. Instrument and equipment revenue was 210 million yuan, down 43.8% year-on-year. The company's service business and diagnostic reagent business continued to maintain a high revenue growth trend. The company's service business segment is mainly an independent medical laboratory business. Its largest laboratory, Guangzhou Procuratorate, achieved operating income of 365 million yuan during the reporting period, a year-on-year increase of 30%. Dean Diagnostics' largest single laboratory, Hangzhou Dean's 2016 revenue is estimated to be between 3.8 and 400 million yuan. Jinyu Testing has not updated the prospectus, only the 2014 Guangzhou Golden Field Experiment was announced in the full fiscal year of 2014. The net profit of the room is 47.41 million yuan, and its estimated income is about 500 million yuan. Therefore, Daan Gene Guangzhou Inspection Center is one of the larger single laboratories in China, and the growth rate of 30% should be the overall growth level of the domestic ICIL industry. Oral Mirror dental mirror mouth mirror,used for mouth or tooth inspcetion Oral Mirror,Dental Mirror,Mouth Mirror Luck Medical Consumables Co.,LIMITED , https://www.luckmedical.com